News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: zare2 post# 153672

Monday, 12/30/2013 8:11:52 AM

Monday, December 30, 2013 8:11:52 AM

Post# of 347009

My take is that we already have the majority of the patients enrolled. Can you say hockey stick enrollment?



This I would only think is capable of happening under very, very careful collaboration between our KOL's and the many followers they may have ..... all trickling down to, hopefully many of Peregrines strategically placed clinical sites.

Not saying either way... but the way Peregrine is sticking to their timeline and limiting information due to lawsuits, its possible that the KOL's are playing a role in the recruiting process as well.

There is a reason the new KOL's are here and I can only hope its to reach out to as many as possible (hopefully many responsible for recruiting at the 100+ clinical sites) and since Peregrine has been adhering to their word to a "T" lately...

a hockey stick enrollment just may be coming in the enrollment of this NSCLC Phase III "SunRise" trial.

The facts are the facts--- patients lived "LONGER" than any other NSCLC trial and I think thats the goal for all of us... to live on.

Dr. Philip Thorpe... one more step has been taken!

Phil will be sorely missed as a colleague and friend. At Peregrine, each of us is pursuing Phil's dream of bringing important drugs to patients who need them based on his basic research. We are more motivated than ever to see this dream through.

http://www.peregrineinc.com/about-us/philip-thorpe-ps-targeting-antibody-inventor.html



"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!